Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 22801446)

1.

Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.

Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM.

Mol Ther. 2012 Aug;20(8):1622-32. doi: 10.1038/mt.2012.130. Epub 2012 Jul 17.

2.

Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, Dilloo D, Heslop HE, Brenner MK, Rooney CM, Leen AM.

Mol Ther. 2009 Sep;17(9):1616-25. doi: 10.1038/mt.2009.140. Epub 2009 Jul 7.

3.

Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.

Gerdemann U, Vera JF, Rooney CM, Leen AM.

J Vis Exp. 2011 May 27;(51). pii: 2736. doi: 10.3791/2736.

4.
5.

Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.

Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM.

Mol Ther. 2013 Nov;21(11):2113-21. doi: 10.1038/mt.2013.151. Epub 2013 Jun 20.

6.

Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.

Hanley PJ, Shaffer DR, Cruz CR, Ku S, Tzou B, Liu H, Demmler-Harrison G, Heslop HE, Rooney CM, Gottschalk S, Bollard CM.

Cytotherapy. 2011 Sep;13(8):976-86. doi: 10.3109/14653249.2011.575356. Epub 2011 May 4.

7.
8.

Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.

Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B.

J Immunol Methods. 2014 Jun;408:101-13. doi: 10.1016/j.jim.2014.05.011. Epub 2014 May 28.

PMID:
24877879
9.
10.

Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.

Lugthart G, Albon SJ, Ricciardelli I, Kester MG, Meij P, Lankester AC, Amrolia PJ.

J Immunother. 2012 Jan;35(1):42-53. doi: 10.1097/CJI.0b013e31823569e2.

PMID:
22130159
11.

Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154.

Khanna N, Stuehler C, Conrad B, Lurati S, Krappmann S, Einsele H, Berges C, Topp MS.

Blood. 2011 Jul 28;118(4):1121-31. doi: 10.1182/blood-2010-12-322610. Epub 2011 Jun 3.

12.

Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases.

Aspord C, Laurin D, Richard MJ, Vie H, Chaperot L, Plumas J.

Am J Transplant. 2011 Dec;11(12):2613-26. doi: 10.1111/j.1600-6143.2011.03722.x. Epub 2011 Aug 29.

13.

Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.

Zandvliet ML, van Liempt E, Jedema I, Kruithof S, Kester MG, Guchelaar HJ, Falkenburg JH, Meij P.

J Immunother. 2011 Apr;34(3):307-19. doi: 10.1097/CJI.0b013e318213cb90.

PMID:
21389867
14.

CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.

Sukdolak C, Tischer S, Dieks D, Figueiredo C, Goudeva L, Heuft HG, Verboom M, Immenschuh S, Heim A, Borchers S, Mischak-Weissinger E, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1480-92. doi: 10.1016/j.bbmt.2013.07.015. Epub 2013 Jul 23.

PMID:
23891747
15.

Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.

Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop HE, Brenner MK, Rooney CM.

J Immunother. 2008 Sep;31(7):665-74. doi: 10.1097/CJI.0b013e318181b4bd.

16.
17.

Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.

Wang Y, Aïssi-Rothe L, Virion JM, De Carvalho Bittencourt M, Ulas N, Audonnet S, Salmon A, Clement L, Venard V, Jeulin H, Stoltz JF, Decot V, Bensoussan D.

Cytotherapy. 2014 Jan;16(1):122-34. doi: 10.1016/j.jcyt.2013.07.008. Epub 2013 Oct 1.

PMID:
24094498
18.

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.

Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G.

Blood. 2010 Apr 1;115(13):2695-703. doi: 10.1182/blood-2009-09-242263. Epub 2010 Jan 28.

19.

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM.

Blood. 2003 Mar 1;101(5):1905-12. Epub 2002 Oct 31.

20.

Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.

Tan LC, Mowat AG, Fazou C, Rostron T, Roskell H, Dunbar PR, Tournay C, Romagné F, Peyrat MA, Houssaint E, Bonneville M, Rickinson AB, McMichael AJ, Callan MF.

Arthritis Res. 2000;2(2):154-64. Epub 2000 Feb 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk